Iain Ross

Interim Principal Executive Officer and Chairman, Silence Therapeutics

Appears in 1 story

Last updated Oct 20, 2026

Stories

Merck KGaA to buy Silence Therapeutics for $1.3 billion

Money Moves

Overseeing the sale of Silence to Merck KGaA

Merck KGaA agreed on October 19 to buy Silence Therapeutics for $1.3 billion in cash, paying $20 per American Depositary Share. That is 130% above Silence's closing price on October 16.

Updated Oct 20